BAR­DA of­fers a tiny start­up up to $812M to cre­ate a US-based drug man­u­fac­tur­er — and the CEO comes with a price goug­ing con­tro­ver­sy on his ré­sumé

BAR­DA has tapped a large­ly un­known start­up to ramp up pro­duc­tion of a list of drugs that may be at risk of run­ning short in the US. And the deal, which comes with up to $812 mil­lion in fed­er­al funds, was inked by a CEO who found him­self in the mid­dle of an ug­ly price goug­ing con­tro­ver­sy a few years ago.

The feds’ new part­ner — called Phlow — won a 4-year “base” con­tract of $354 mil­lion, with an­oth­er $458 mil­lion that’s on the ta­ble in po­ten­tial op­tions to sus­tain the out­fit. That would make it one of the largest awards in BAR­DA’s his­to­ry.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE